322 - Importance of Prodrug-activating Enzymes in Drug Development and Precision Pharmacotherapy

Session Chair(s)

• Hao-Jie Zhu

  University of Michigan

This session will discuss how genetic variants and tissue-specific expression of drug-metabolizing enzymes could affect the activation, pharmacokinetics, and therapeutic efficacy of various prodrugs with a focus on antiviral and anticancer medications. The session will stimulate the discussion regarding how to use genetic variants and tissue-specific proteomics information of drug-metabolizing enzymes to improve the design and delivery of prodrugs and enhance the efficacy and safety of prodrug pharmacotherapy.

Presentations:

• 3:30 PM – 3:32 PM

  Introduction
• 3:32 PM – 3:55 PM

  Pharmacogenetics of Kinases and Its Impact on the Activation of Nucleotide Reverse Transcriptase Inhibitor Prodrugs
  

  Speaker: Namandjé Bumpus – Johns Hopkins University
• 3:55 PM – 4:18 PM

  Design of Anticancer Prodrugs for Site-specific Activation in Tumor Tissues through Bioreduction and Proteolysis
  

  Speaker: Longqin Hu – Rutgers University
• 4:18 PM – 4:32 PM

  Proteomics of Drug-metabolizing Enzymes and Its Implications in the Development of Anti-COVID-19 Prodrugs
  

  Speaker: Hao-Jie Zhu – University of Michigan
• 4:32 PM – 4:47 PM

  Proteomics of Drug-metabolizing Enzymes and Its Implications in the Development of Anti-COVID-19 Prodrugs
  

  Speaker: Joy Feng – Gilead
• 4:47 PM – 4:59 PM

  Ethanol Inhibits the Metabolism of the Multiple Sclerosis Drug Dimethyl Fumarate to its Active Metabolite and Decreases Brain Exposure
  

  Presenting Author: Bing Yang – University of Tennessee Health Science Center
• 4:59 PM – 5:00 PM

  Conclusion